

Phone: 732-390-7750 Fax: 844-683-2244 AsteraCancerCare.org
PATIENT REFERRAL FORM NEUROLOGY

Patient Name:			Pt. DOB://		
	Last	First	Middle		
Patient Address: _					
Patient City:			Pt. State:	Pt. Zip:	
Patient Phone: ()			Pt. Height:	in.
DX:				Pt. Weight:	lbs.
Insurance:				ID#:	
Referred by:		NPI#:			
Office Contact (Re	quired):			ce Ph: () ce Fax: ()	
Office Administrat	or (Required)	:		tor Ph: ()	
	ity I Monroe	■Robbinsville I	□Brick □Bridgewate □Rutherford □Som	er □East Brunswick erset □Toms River	
		on including nam		act dosage, and directions	;
☐ Copy of current i	nsurance card				
☐ Recent MD consu	ultation notes:	relevant disease	being treated must	be mentioned in report	
☐ Allergies and cur	rent medication	n list			
☐ Current labs requ	ired for specifi	c medication, as	noted on the follow	ing page(s) of this form	
Has the patient init	iated treatmen	t at your office?	□ Y	es 🗆 No	
☐ If any future lab	tests are neede	d, please provide	e patient with a pres	cription, and have patient	bring on
day of treatment. F	Results will be s	ent to referring p	ohysician.		
Please note:					

- 1. A Letter of Medical Necessity is required for all patients receiving their initial infusion at Astera (letter must include diagnosis, previous treatments/response to treatments and be on letterhead with physician signature).
- 2. Benefit investigations, copay assistance and prior authorizations will be handled by the Astera precert staff if required by the payer. Right to auto-substitute biosimilars based on payer's preference. Detailed clinical notes providing supportive documentation are required for authorization requests which may take 3-5 business days depending on the payer and receipt of complete documentation from the referring office. The precert staff will update the referring doctor's office during this process and contact the patient to discuss cost and financial assistance options. For certain medications, patients will be required to register/enroll with the pharmaceutical company prior to rendered services and will receive a call from an Astera Financial Counselor to assist with this process.
- 3. A pretreatment education session will be provided by an Advanced Practice Provider.
- 4. Once the infusion is complete, a follow-up notice will be faxed to the to the referring provider.

Patient Name:				DOB:	DOB:/			
	Last	First	Middle					
Please check the box for medication requested, attach required documentation as noted below, and fax all documents to our office at 844.683.2244. Once all documentation is received, we will contact your patient to schedule an appointment. Thank you!								
Medication Note: Progress	·	uired Current La	b Results vithin the previous 6	5 months for all nev	v and rene	ewed prescriptions.		
□ Briumvi	CBC, Quantitative Serum Immunoglobulin, Prior to initiation – Hep B Serology (Hep B surface antigen, Hep B surface antibody and Hep B core antibody) Confirm No Vaccinations within 4 Weeks of Therapy							
☐ Evenity	CMP, Dexa Scan within 2 years Confirm pt. has not had an MI or stroke within previous year							
□ IVIG	Hematocrit, Hemoglobin, IgG Concentrations, Platelets, Renal Function Tests, Urine Output Provide dose basis in mg/kg. Doses will be rounded to the nearest vial size available.							
☐ Kisunla	Prior to initiation – confirm presence of amyloid beta pathology and brain MRI (within 1 year), completed Benefits investigation and Care Coordination Forms							
☐ Leqembi	Prior to initiation – confirm presence of amyloid beta pathology and brain MRI (within 1 year)							
□ Ocrevus	CBC, prior to initiation - Hep B Serology (Hep B surface antigen, Hep B surface antibody and Hep B core antibody) ☐ Confirm No Vaccinations within 4 Weeks of Therapy							
□ Radicava □ Rituxan/Riab	CBC, prior to init Hep B core antib	tiation - Hep B Sero body)	d indications only - ology (Hep B surfac 4 Weeks of Therap	e antigen, Hep B su	•			
□ Soliris	Meningococcal '	Vaccination						
☐ Tysabri	MRI (MS patients), TOUCH Program Registration							
□ Vyepti	None							
☐ Vyvgart	Anti-AChR Antibo	dy Positive, No Liv	ve Vaccines During	Therapy				
□ Vyvgart Hytr	ulo (SQ – CIDP and Anti-AChR Antibo Confirm no active	dy Positive (Myast	is) :henia Gravis only).	No live vaccines du	ıring thera	пру.		